ZFZheng Fang

Zheng Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zheng Fang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Picoeukaryote-based biohybrid microrobots for active delivery in the kidney

    by Zhengxing Li, Dan Wang, Hao Luan, An-Yi Chang, Zheng Fang, Lei Sun, Junyi Ji, Wei-Ting Shen, Yiyan Yu, Yiyang Yan, et al.

    Confined spaces in the human body pose substantial challenges for biomedical procedures. Navigating these ultrasmall environments is essential for precise drug delivery, improving treatment outcomes and reducing adverse effects. Microrobots offer a promising approach to accessing these complex microenvironments. Here, we show a biohybrid microrobot based on picoeukaryotes, engineered as a cargo carrier for active delivery in tight in vivo spaces. The microrobot exhibits strong in vitro motility through narrow two-dimensional and complex three-dimensional networks and, in vivo, achieves outstanding kidney penetration, uniform distribution, and >48-hour retention while resisting flow shear and immune clearance, with excellent biosafety. Their ability to retain functionality and sustain propulsion within the confined and complex kidney vasculatures and interstitial spaces underscore their potential for long-term, active delivery in confined biological environments. The picoeukaryote-based biohybrid microrobot system represents a major advancement in active drug delivery, especially tailored to the challenging microenvironments of the kidney.


  • Top Cited Papers
    Open Access

    Inhalable biohybrid microrobots: a non-invasive approach for lung treatment

    by Zhengxing Li, Zhongyuan Guo, Fangyu Zhang, Lei Sun, Hao Luan, Zheng Fang, Jeramy L. Dedrick, Yichen Zhang, Christine Tang, Audrey Zhu, et al.

    Amidst the rising prevalence of respiratory diseases, the importance of effective lung treatment modalities is more critical than ever. However, current drug delivery systems face significant limitations that impede their efficacy and therapeutic outcome. Biohybrid microrobots have shown considerable promise for active in vivo drug delivery, especially for pulmonary applications via intratracheal routes. However, the invasive nature of intratracheal administration poses barriers to its clinical translation. Herein, we report on an efficient non-invasive inhalation-based method of delivering microrobots to the lungs. A nebulizer is employed to encapsulate picoeukaryote algae microrobots within small aerosol particles, enabling them to reach the lower respiratory tract. Post nebulization, the microrobots retain their motility (~55 μm s-1) to help achieve a homogeneous lung distribution and long-term retention exceeding five days in the lungs. Therapeutic efficacy is demonstrated in a mouse model of acute methicillin-resistant Staphylococcus aureus pneumonia using this pulmonary inhalation approach to deliver microrobots functionalized with platelet membrane-coated polymeric nanoparticles loaded with vancomycin. These promising findings underscore the benefits of inhalable biohybrid microrobots in a setting that does not require anesthesia, highlighting the substantial translational potential of this delivery system for routine clinical applications.